Indication
Severe Marrow Failure
1 clinical trial
4 products
2 drugs
Clinical trial
A Phase II Trial of HSCT for the Treatment of Patients With Fanconi Anemia Lacking a Genotypically Identical Donor, Using a Risk-Adjusted Chemotherapy Only Cytoreduction With Busulfan, Cyclophosphamide and FludarabineStatus: Recruiting, Estimated PCD: 2024-07-01
Product
BusulfanDrug
cyclophosphamideProduct
FludarabineProduct
Rabbit ATGDrug
FilgrastimProduct
Peripheral blood stem cell